logo
Top Stories
56
45
GM-Recall-111717-lg.jpg

General Motors Co. (GM) is recalling nearly 49,000 trucks worldwide to fix a fuel tank issue that can increase the risk of a fire. The recall covers Chevrolet Silverado 3500 and GMC Sierra 3500 trucks from the 2011 through 2015 model years, all equipped...

Japan had a merchandise trade surplus of 285.385 billion yen in October, the Ministry of Finance said on Monday. That was shy of expectations for a surplus of 330.0 billion yen and was down from 670.17 billion yen in September. Exports climbed 14.0...

US-Military-Gen-Dunford-111717-lg.jpg

The Chairman of the Joint Chiefs of Staff (CJCS) has warned that the United States' military advantage against near-peer competitors Russia and China is eroding, and it is no longer as decisive as it was some years ago. General Joseph Dunford sounded...

sharessubdued-111717-lg.jpg

Asian stocks are broadly lower on Monday as Japanese export growth weakened unexpectedly in October and a political impasse in Germany dent investor risk appetite and helped spur demand for safe-haven assets. Gold prices dipped ahead of this week's...

Shakira-111517-lg.jpg

Shakira has announced that she is postponing her European tour until next year to rest and fully recover from a hemorrhage on her vocal cords. The pop diva is disappointing thousands of her fans days after announcing the cancellation of her El Dorado...

stocklower-111317.jpg European stocks may open a tad lower on Monday, with U.K. politics likely to be in focus after reports that 40 Tory MPs are prepared to sign a letter of no confidence in leader Theresa May following Ms May's disastrous conference speech. If eight more...
mixedmarket-111317.jpg Asian stocks closed on a mixed note on Monday as U.S. President Donald Trump's tour of Asia continued and investors awaited a slew of data from China, Japan and Australia this week for directional cues. Concerns about political instability in the U.K....
ZUMIEZ-111317.jpg Shares of Zumiez Inc. (ZUMZ) have risen more than 50% in the last three months while the NASDAQ Composite is up only 8% during the same period.
sharelower2-111317.jpg European stocks were subdued on Monday as ongoing concerns over Brexit negotiations and U.S. tax reform plans continued to keep investors nervous. Disappointing bank lending data from China also weighed on markets on a light day on the economic front....
More
AlexAzar-111317.jpg President Donald Trump announced Monday he is nominating former pharmaceutical company executive Alex Azar as secretary of the U.S. Health and Human Services Department. Azar, a prominent Obamacare critic, previously served as president of Lilly USA,...
More
OrrinHatch-111717.jpg Republican members of the Senate Finance Committee voted Thursday to approve their version of tax reform legislation. The committee voted 14 to 12 in favor of the $1.5 trillion tax reform bill, with the vote coming down strictly along party lines....
More
Moodys-India-111717.jpgMoody's Investors Service on Friday raised the sovereign ratings of India for the first time since 2004, citing economic and institutional reforms. The sovereign rating was lifted to Baa2 from Baa3 and the rating outlook was changed to 'stable' from 'positive'. The upgrade has placed India's rating at par with those of Italy and the Philippines.
More
BillGates-CuringAlzheimers-111317.jpg
Billionaire and Microsoft co-founder Bill Gates is making a personal investment of $50 million into the Dementia Discovery Fund, a venture capital fund that invests in projects and companies to develop treatments for the brain-wasting disease. The investment is not part of Gates' philanthropic Bill & Melinda Gates Foundation, which has focused primarily on infectious diseases.
More
AbercrombieFitch-111717.jpg
Apparel retailer Abercrombie & Fitch Co. on Friday reported a 28 percent increase in profit for the third quarter from last year on higher sales. Both revenue and adjusted earnings per share for the quarter beat analysts' estimates. The company's shares are gaining more than 20 percent in pre-market activity.
More
Today's Daily Dose brings you news about Aerie's progress in phase II trial of glaucoma drug in Japan; phase III results of Egalet's pain pill; FDA approval of GlaxoSmithKline's COPD drug; expanded labeling for Pfizer's kidney cancer drug Sutent and Roche's double blessing on Thursday. More
Shares of Catalyst Pharmaceuticals Inc. (CPRX) are up an impressive 179% year-to-date while the iShares NASDAQ Biotechnology Index ETF (IBB) has gained just 17% during the same period. More
Zimbabwe's leader Robert Mugabe has vowed to stay in power for several weeks, despite intensifying pressure on him to stand down, according to reports. In a live TV address, Mr Mugabe said he would preside over the ruling party's congress in December. The...
More
HealthIQ-111517.jpg Health IQ Insurance Services, a startup focused on providing life insurance for health-conscious individuals, said it has secured $34.6 million in Series C funding, led by Andreessen Horowitz. To date, the company has raised a total of $81 million in funding mostly from its existing investors.
More
Follow RTT
Economic Calendar
DateIndicatorPeriodCountry
11/20/17 0:0Wholesale Sales (Q-o-Q)Q3 Singapore
11/20/17 0:0Wholesale Sales (Y-o-Y)Q3 Singapore
11/20/17 CPI - EU Harmonised (M-o-M)OCT Iceland
11/20/17 CPI - EU Harmonised (Y-o-Y)OCT Iceland
11/20/17 Current Account Balance - BoPSEP Greece
11/20/17 Capital Account Balance - BoPSEP Greece
Complete Economic Calendar
FDA Calendar
Event DateSymbolDrug NameEvent Name
02/14/18AMAG, AMAGMakena subcutaneous auto-injector (sNDA)FDA decision on subcutaneous version of Makena to reduce the risk of preterm birth
01/24/18SGYPTRULANCE (sNDA)FDA decision on TRULANCE for the treatment of adults with irritable bowel syndrome with constipation
01/12/18LGNDLUXTURNA (BLA)FDA decision on LUXTURNA for inherited retinal disease
01/12/18ONCELUXTURNA (BLA)FDA decision on LUXTURNA for treatment of patients with vision loss due to confirmed biallelic RPE65 mutation-associated retinal dystrophy.
01/10/18LLYAbemaciclib (NDA)FDA decision on Abemaciclib for the treatment of advanced breast cancer
Complete FDA Calendar